Gapping up
In reaction to earnings/guidance:
- BOOT +6.6%, NTUS +6.1%, EXEL +5.2%, PKI +5.2%, FOLD +4.1%, TLYS +3.9%, EXAS +3.6%, AVTR +3.3%, EBS +3%, NSTG +2.3%, GILD +2%, CDNA +1.5%, AZZ +1.2%, NVCR +1%
Other news:
- MESO +70.3% (single dose of Rexlemestrocel-L provides substantial and durable reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure)
- BNGO +24.3% (announces the kick-off of its next-generation cytogenomics symposium, the largest event yet to showcase saphyr's utility in genome analysis for genetic disease and cancer)
- SECO +23.2% (announces receipt of preliminary non-binding "going private" proposal)
- LLY +14.5% (Donanemab slows clinical decline of Alzheimer's disease in "positive" Phase 2 trial)
- ORIC +11.2% (provides corporate update and highlights key 2021 milestones; Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021)
- NIO +11% (NIO partners with NVIDIA (NVDA) to develop a new generation of automated driving electric vehicles)
- XCUR +10.5% (granted two fast track designations for Cavrotolimod (AST-008) from the FDA)
- WBAI +7.5% (expects to issue ~$14.4 mln worth of its Class A ordinary shares as consideration to acquire bitcoin mining machines owned by the Sellers)
- PASG +7.3% (announces plan to deliver on multiple meaningful catalysts in 2021)
- ATRA +6.8% Presenting at JP Morgan Healthcare Conf)
- PACB +5.2% (SoftBank has taken a 6% stake in PACB, according to Bloomberg)
- BLUE +5.1% (Bluebirdbio to separate oncology business into independent company)
- CYTK +4.3% (FDA granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy)
- BIDU +3.4% (confirms plans to establish an intelligent EV company and form strategic partnership with Geely (GELYY))
- KXIN +3.2% (announces entry into a vehicles supply contract between Haitaoche Limited and China National Vehicles Import & Export Company)
- RYI +2.9% (appoints James Claussen as CFO, effective January 11)
- DYN +2.8% (reports Myotonic Dystrophy Type 1 Program achieves robust RNA Knock down of toxic human nuclear DMPK in preclinical study)
- VXX +2.7% (trading higher with futures softer in pre=mkt)
- BIIB +2.2% (Biogen: Atalanta announced strategic collaborations with Biogen (BIIB) and Roche's (RHHBY) Genentech)
- SYRS +2.1% (announces strategic priorities and expected milestones)
- AVXL +2% (awarded ~$ 1 mln from The Michael J. Fox Foundation for Parkinson's Research to develop ANAVEX2-73 for the treatment of Parkinson's disease)
- RIGL +2% (provides business update )
Analyst comments:
- PLAN +3.3% (upgraded to Overweight from Neutral at Piper Sandler; upgraded to Buy from Hold at Jefferies)
- DDOG +2.1% (upgraded to Buy from Hold at Jefferies)
- CRWD +1.2% (upgraded to Buy from Hold at Jefferies)